On February 1, 2024 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference (Press release, Revolution Medicines, FEB 1, 2024, View Source [SID1234639790]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Conference Dates: February 7-8, 2024
Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, February 7, 2024
Location: New York, NY; webcast available
TD Cowen 44th Annual Health Care Conference
Conference Dates: March 4-6, 2024
Fireside Chat Time/Date: 2:10 p.m. Eastern on Wednesday, March 6, 2024
Location: Boston, MA; webcast available

To access the live webcasts of the presentations, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, replays of the webcasts will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following each conference.